In June, Promega proudly announced the ten winners of the 2024 Promega iGEM Grant. These extraordinary teams have been hard at work preparing for the iGEM Grand Jamboree, which will take place from October 23-26, 2024, in Paris, France. We interviewed a handful of this year’s grant recipients to learn more about their projects and journeys they’ve taken to reach this exciting milestone. Below are stories from four of the winning teams.
According to the National Human Genome Research Institute, synthetic biology is “a field of science that involves redesigning organisms for useful purposes by engineering them to have new abilities”. Synthetic biology has a broad range of applications, from manufacturing pharmaceuticals and other biologically active chemicals and biofuels, to accelerating the adoption of plant-based burgers (1).
At the heart of the synthetic biology revolution is the rapid technological advancement—and accompanying drop in costs—of DNA oligonucleotide synthesis. Typically, synthetic biology researchers use oligonucleotides as building blocks to assemble genes of interest that are then introduced into, and expressed by, a different organism. For example, to create the plant-based Impossible Burger, the soy leghemoglobin gene (normally found in the root nodules of leguminous plants) was synthesized and expressed in yeast cells (1). This component gives the burger its meaty flavor and appearance of “bleeding” when cooked.
Continue reading “Synthetic Biology: Minimal Cell, Maximal Opportunity”
On June 15, 2023, we announced the winners of the 2023 Promega iGEM grant. Sixty-five teams submitted applications prior to the deadline with projects ranging from creating a biosensor to detect water pollution to solving limitations for CAR-T therapy in solid tumors. The teams are asking tough questions and providing thoughtful answers as they work to tackle global problems with synthetic biology solutions. Unfortunately, we could only award nine grants. Below are summaries of the problems this year’s Promega grant winners are addressing.
The UCSC iGEM team from the University of California–Santa Cruz is seeking a solution to mitigate the harmful algal blooms caused by Microcystis aeruginosa in Pinto Lake, which is located in the center of a disadvantaged community and is a water source for crop irrigation. By engineering an organism to produce microcystin degrading enzymes found in certain Sphingopyxis bacteria, the goal is to reduce microcystin toxin levels in the water. The project involves isolating the genes of interest, testing their efficacy in E. coli, evaluating enzyme production and product degradation, and ultimately transforming all three genes into a single organism. The approach of in-situ enzyme production offers a potential solution without introducing modified organisms into the environment, as the enzymes naturally degrade over time.
Endometriosis is a condition that affects roughly 190 million (10%) women of reproductive age worldwide. Currently, there is no treatment for endometriosis except surgery and hormonal therapy, and both approaches have limitations. The IISc-Bengaluru team at the Indian Institute of Science, Bengaluru, India, received 2023 Promega iGEM grant support to investigate the inflammatory nature of endometriosis by targeting IL-8 (interleukin-8) a cytokine. Research by other groups has snow that targeting IL-8 can reduce endometriotic tissue. This team will be attempting to create an mRNA vaccine to introduce mRNA for antibody against IL-8 into affected tissue. The team is devising a new delivery mechanism using aptides to maximize the delivery of the vaccine to the affected tissues.
Continue reading “2023 Promega iGEM Grant Winners: Tackling Global Problems with Synthetic Biology Solutions”Today’s guest blog about the 2020 virtual iGEM Giant Jamboree is written by Abigail Conner, Co-Team Leader of iGEM King’s College London (KCL).
In October 2019, I returned to London from Boston feeling elated after an unforgettable week at the Giant Jamboree. My team, Capacity, had just won a Silver Medal. I had the privilege of presenting in front of the judges about our work. The Giant Jamboree presented me with a vision of where Synthetic Biology will take us and its potential to radically transform our society for the better. Words cannot describe the deep sense of pride I felt to be a part of this community. For the first time, I felt truly empowered as a young scientist and was hugely inspired by the brilliance of my peers. As a result, I was beyond happy to assume the role of Team Leader of KCL’s 2020 team.
Almost immediately after touching down in the United Kingdom, I began to plan our project. Throughout the recruitment process and setting up applications, Stephanie Avraamides—the Head of Human Practices in Capacity—joined me in leading the team. As Co-Team Leaders, we would establish Renervate, a team of 19 undergraduate students from various STEM backgrounds, from Nutrition to Biomedical Engineering. Although we were fortunate to have met up in person several times before March, the onset of the COVID-19 pandemic scattered us across the world. Our team members represent sixteen different countries, meaning we had to navigate a range of time zones when working virtually. Despite this, we adapted to the virtual setting and worked tirelessly to develop Renervate. Come November, we would be rewarded for our endurance and commitment. I am thrilled to say that Renervate won a Gold Medal, Best Therapeutics Project, and nominations for Best Model and Best Supporting Entrepreneurship at last year’s Virtual Giant Jamboree.
Continue reading “Reflections: King’s College London iGEM 2020, Renervate and Future Prospects”Today’s guest blog about the 2020 virtual iGEM Giant Jamboree is written by Lancia Lefebvre, Team Leader of iGEM Concordia.
After a year of full-time work, I joined our team of 16 undergraduate students to live-stream the virtual iGEM Giant Jamboree from the isolation of our respective apartments. Together in a separate zoom call and Facebook chat, we fired off messages as awards were announced. ‘OMG Toulouse won best poster! Did you see Aachen’s project?’ Then came the Software Track award, our track, and boom! “Concordia-Montreal are the Software Track Winners for iGEM Giant Jamboree 2020!”
Firework and heart emojis exploded in our chat and on my zoom call, mouths gaped in shock and pride. Our AstroBio database for differential gene expression in microgravity conditions had won! Innumerable lines of code; hours of consultation with NASA bioinformaticians, bioethicists and coding pros; detailed graphic design; and most of all passionate teamwork had brought us this distinction. A gold medal and an inclusion nomination soon followed. This nomination we hold close to our heart as we continuously collaborate on a safe, warm and welcoming team structure. Supporting each other and working together are core iGEM values, which lead to collaborative and stronger solutions to world problems through the application of synthetic biology solutions.
Continue reading “Exploring the Virtual iGEM Giant Jamboree with iGEM Concordia”Synthetic biology—genetically engineering an organism to do or make something useful—is the central goal of the iGEM competition each year. After teams conquer the challenge of cloning their gene, the next hurdle is demonstrating that the engineered gene is expressing the desired protein (and possibly quantifying the level of expression), which they may do using a reporter gene.
Reporters can also play a more significant role in iGEM projects when teams design their organism with reporter genes to detect and signal the presence of specific molecules, like environmental toxins or biomarkers. Three of the iGEM teams Promega sponsored this year opted to incorporate some version of NanoLuc® Luciferase into their projects.
NanoLuc® luciferase is a small monomeric enzyme (19.1kDa, 171 amino acids) based on the luciferase from the deep sea shrimp Oplophorus gracilirostris. This engineered enzyme uses a novel substrate, furimazine, to produce high-intensity, glow-type luminescence in an ATP-independent reaction. Unlike other molecules for tagging and detecting proteins, NanoLuc® luciferase is less likely to interfere with enzyme activity and affect protein production due to its small size.
NanoLuc® Luciferase has also been engineered into a structural complementation reporter system, NanoBiT® Luciferase, that contains a Large subunit (LgBiT) and two small subunit options: low affinity SmBiT and high affinity HiBiT. Together, these NanoLuc® technologies provide a bioluminescent toolbox that was used by the iGEM teams to address a diverse set of biological challenges.
Here is an overview of each team’s project and how they incorporated NanoLuc® technology.
Continue reading “NanoLuc: Tiny Tag with a Big Impact”
After attending the iGEM Giant Jamboree last year and being completely blown away by the projects presented (check out this article or this one), I didn’t think I’d be as astonished this year. I attributed part of the awe I felt over the caliber and quality of the projects to my wide-eyed naiveté, having never attended the event before. The second time around, the “first-time” novelty long worn off, I didn’t expect to feel that same level of amazement.
I couldn’t have been more wrong.
After three days of impressive presentations, I once again felt that same astonishment as I prepared to watch the presentations of the 6 finalists. With good reason—the projects presented by the six finalists completely blew my mind!
Continue reading “The Future of Synthetic Biology: A Recap of iGEM 2019”Today’s blog is guest-written by Wihan Adi, a Master’s student majoring in physics at Justus-Liebig-University in Giessen and team member of iGEM Marburg. Although his background is in nuclear and particle physics, his research interests shifted toward affordable biosensors for point-of-care cancer detection, which is how he ended up doing microbiology for iGEM.
Back in March when the iGEM season had just started, Maurice, a fellow iGEM Marburg team member, told me that he was exchanging emails with Margaretha Schwartz from Promega. Given my background as a physics student, Promega was not a household name for me at the time. “So, are you interested in automating a plasmid purification protocol?” asked Maurice. He told me that Promega was willing to supply the Wizard® MagneSil® Plasmid Purification System for this purpose; that was another name that added to my confusion.
This year, iGEM Marburg is aiming to establish a fast phototrophic organism as a synthetic biology chassis. For this goal we chose Synechococcus elongatus UTEX 2973, with a reported doubling time of 90 minutes. More specifically, we are creating an easy to use toolbox to empower rapid design testing, including genome engineering tools, self-replicating plasmid systems, natural competence and a Golden Gate-based part library. Our team chose to work on phototrophic organisms because we envision accelerating research in this particular field. (Note: Last year, Marburg’s iGEM project won the Grand Prize!)
Continue reading “It Takes a Village: Automating Plasmid Purification for iGEM”Formal judgment in any context is nerve-racking. Scientists, familiar with being judged, rely on others to evaluate (and hopefully accept) everything from a PhD thesis defense to grant proposals and peer-reviewed journal article submissions. The frustrating part is not knowing exactly what the judges are looking for. Sure there are requirements and guidelines to follow—but how are the judges going to interpret them? It would be a whole lot easier if we could just peek into their minds. Unfortunately for most, that fantasy isn’t likely to turn into reality.
But if you are part of an iGEM team, today is your lucky day! Our own Preeta Guptan volunteers as a judge for the iGEM competition, and in today’s article, you will get her insider’s perspective about what iGEM judges look for. You will also get some tips to help you excel in the iGEM competition—and effectively communicate about science in general.
Preeta is an External Innovation Manager at Promega, which means she seeks out and investigates technology that might be valuable for Promega to license or acquire. The opportunity to scout up-and-coming synthetic biology advances was one reason she wanted to be an iGEM judge, but curiosity was at the core of her decision. Preeta and the other judges bring their unique perspectives and experiences to each iGEM project and team they evaluate. Here are some suggestions from Preeta:
Continue reading “Sci Comm Tips From An iGEM Judge”Imagine you are a high school student living in a community devastated by gun violence and death. In the U.S., this could be one of many communities, but it happens to be Baltimore which had 301 deaths due to gun violence in 2017 (with a per capita rate well above other large cities). Then imagine you were part of an organization within that community that helped you, along with other students, gain knowledge and skills to come up with a viable solution to the problem using synthetic biology.
This is exactly how the Baltimore Bio-Crew came up with their iGEM project, Coagulance Rx. The Baltimore Bio-Crew decided to tackle this community issue head-on. One team member, Mercedes Ferandes, reflected, “Living in Baltimore City, I have not only witnessed gun violence in front of me, but have had family members and friends die from it. I wanted to try to decrease the amount of deaths by gun violence using iGEM.”
After some research, they discovered that many of the gun violence deaths were due to blood loss and could have been prevented. The impoverished neighborhoods where this violence occurs lack the resources to provide timely emergency medical treatment. Many of these deaths can be attributed to delayed arrival of emergency response teams—wait times for an ambulance can be over an hour.
Although there were several contributing factors beyond their control, the team wanted to address this problem by focusing on blood clotting and how it could be helpful as a quick temporary treatment for open wounds. This solution could offer a reliable, cost efficient way to save lives by slowing or stopping blood loss until a victim could get medical attention. The team decided to pursue the use of snake venom after coming across some previous iGEM projects that had used it for clotting. Team member Henry Ryles pointed out that the need for snake venom powerful enough to clot blood quickly led them to choose the venom of the Russell’s Viper
(Daboia russelii).
